Biocartis

Company

Investment-firm

Last deal

$1.41M
Local Amount - EUR 1.2M

Amount

Grant

Stage

30.09.2020

Date

3

all rounds

$338.83M

Total amount

Financing round

General

About Company
Biocartis is a molecular diagnostics company.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

Biocartis is a commercial-stage molecular diagnostics company that has developed a proprietary diagnostic platform called Idylla™. This platform is fully automated and provides accurate molecular information from any biological sample. It addresses the demand for personalized medicine by allowing fast and effective treatment selection and monitoring. Biocartis is focused on developing tests for oncology and infectious diseases, which are the fastest and largest growing segments of the molecular diagnostics market. Their vision is to enable personalized medicine for patients worldwide by making molecular testing convenient and suitable for any lab.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Asuragen

Asuragen

Asuragen is a fully integrated diagnostics company specializing in mRNA-based solutions for molecular oncology and early cancer detection.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Austin, TX, USA

total rounds

5

total raised

$80M
Genedrive Plc

Genedrive Plc

genedrive offers affordable, user-friendly diagnostic tests for infectious diseases and animal applications.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Manchester, UK

total rounds

4

total raised

$18.2M
BioMAdvanced Diagnostics

BioMAdvanced Diagnostics

BioMAdvanced Diagnostics is a MedTech start-up that develops diagnostic aid tools for personalized medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Nantes, France

total rounds

2

total raised

$3.21M
Multiplicom

Multiplicom

Multiplicom is a biotech company that develops molecular diagnostic kits.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Medical

Location

Bel, 2440 Geel, Belgium

total rounds

3

total raised

$10.37M

Financials

Funding Rounds
9
3

Number of Funding Rounds

$338.83M

Money Raised

Their latest funding was raised on 30.09.2020. Their latest investor Luc Verelst. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
30.09.2020
1
$1.41M
Local Amount - EUR 1.2M
28.11.2017
$94.79M
Local Amount - EUR 80M
04.09.2014
3
$83.43M
Local Amount - EUR 64.5M
Flanders Innovation and Entrepreneurship (VLAIO)

Flanders Innovation and Entrepreneurship (VLAIO)

The Flemish regional government in Belgium operates a research fund for basic and applied research.

Sector

Media

Subsector

Publishing

Keywords

Government, Non-Profit, Association

Location

Brussels, Belgium

count Of Investments

46

count Of Exists

3
Investments
2
Date 
name 
Lead 
type 
Raised 
21.06.2021
Yes
$3.2M
19.06.2012
No
$2.04M
Local Amount - AUD 2M
Geneprodx

Geneprodx

Geneprodx is a clinical laboratory specializing in molecular diagnostic of thyroid cancer.

Sector

Medical Equipment and Services

Subsector

Medical Services

Keywords

Health Care, Biotechnology, Health Diagnostics

Location

Santiago, Santiago Metropolitan Region, Chile

total rounds

3

total raised

$6.2M
Immunexpress

Immunexpress

Immunexpress Pty Ltd is a molecular diagnostics company that develops clinical assays for the management of immune disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Seattle, WA, USA

total rounds

6

total raised

$67.02M
Co-Investors
Investors
17
3

Number of lead investors

17

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series D
Yes
Series D, Series E

Luc Verelst

count Of Investments

1
Philips Venture Capital Fund

Philips Venture Capital Fund

Philips Venture Capital Fund is a global venture capital fund that invests in technology startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Eindhoven, Netherlands

count Of Investments

11

count Of Exists

5
Johnson & Johnson Development Corporation

Johnson & Johnson Development Corporation

JJDC is the venture capital arm of Johnson & Johnson, investing in pharmaceuticals, medical devices, and consumer healthcare.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services, Biotechnology

Location

New Brunswick, NJ, USA

count Of Investments

107

count Of Exists

43

People

Founders
2

Nader Donzel

Nader Donzel is the head of operations and finance at Scitec Research. Prior to Scitec Research, he served [Biocartis](https://www.crunchbase.com/organization/biocartis), holding various positions as the general manager of the business unit of Switzerland, chief operating officer, and the managing director. Donzel holds a master’s degree in informatics and computer science from [Ecole polytechnique fédérale de Lausanne](https://www.crunchbase.com/organization/epfl) and an MBA from [Babson College](https://www.crunchbase.com/organization/babson-college#/entity).

organization founded

1

Nader Donzel

Rudi Pauwels
Rudi Pauwels

Rudi Pauwels

Rudi Pauwels, CEO of Biocartis, founded the company in 2007. He also (co)founded several other biotech companies, including Tibotec, Virco and Galapagos Genomics. He also serves as Executive Chairman. Rudi is a pharmacist who started as a researcher at the Rega Institute for Medical Research in Leuven, Belgium, an academic research center that is internationally renowned for its pioneering work in the field of antiviral chemotherapy. For more than two decades Rudi has focused on the search and development of anti-HIV drugs – a number of which have been approved and introduced on the market – and the development of diagnostic tools to allow personalized HIV treatment. Both his research and entrepreneurial career are driven by the needs of patients and a passion for advancing and medicine and leaving his mark. Rudi is (co-)author of more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Rudi has a PhD in Pharmacology from KU Leuven.

current job

Tibotec
Tibotec

count Of Investments

1

Rudi Pauwels

Employee Profiles
32
Jean-Marc Roelandt

Jean-Marc Roelandt

Chief Financial Officer

Sarah Thiollet

Design manager-design team

Leo McHugh

Leo McHugh

Principal Biostatistician

Piet Houwen

Piet Houwen

Chief Operating Officer

Kristina Kalous

Territory sales manager

Raf Pasmans

Business director export

Benoit Devogelaere

Benoit Devogelaere

Chief Technology Officer

Herman Verrelst

Herman Verrelst

Chief Executive Officer

Activity

Recent News
6
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month